SCHEMBL22816237

SCHEMBL22816237

FC1(F)CCN(c2ccc(C3=CCC4(CC3)OCCO4)cc2)CC1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LGMN Q99538 1/20 0.38
TBK1 Q9UHD2 2/20 0.35
IKBKE Q14164 1/20 0.35
SUV39H2 Q9H5I1 2/20 0.34
USP2 O75604 2/20 0.34
ALDH1A1 P00352 2/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
HSD17B10 Q99714 2/20 0.34
HPGD P15428 1/20 0.34
ALOX12 P18054 1/20 0.34
MAPK1 P28482 1/20 0.34
CYP3A4 P08684 2/20 0.31
TSHR P16473 1/20 0.31
L3MBTL3 Q96JM7 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL612703 0.87 LGMN (0.37) LGMNTBK1IKBKESUV39H2USP2
SCHEMBL22816721 0.84 ALDH1A1 (0.41) LGMNTBK1IKBKESUV39H2ALDH1A1
SCHEMBL14403246 0.81 TBK1 (0.43) TBK1IKBKESUV39H2
SCHEMBL745424 0.76 TBK1 (0.39) TBK1IKBKESUV39H2
SCHEMBL23484661 0.76 SUV39H2 (0.40) TBK1IKBKESUV39H2CYP1A2CYP2C9
SCHEMBL2384758 0.73 HTR2C (0.40) TBK1IKBKESUV39H2HPGD
SCHEMBL14117573 0.73 TBK1 (0.39) TBK1IKBKESUV39H2ALDH1A1HPGD
SCHEMBL13832397 0.73 SUV39H2 (0.41) TBK1IKBKESUV39H2ALDH1A1HSD17B10
SCHEMBL23484653 0.73 USP2 (0.38) TBK1IKBKESUV39H2USP2ALDH1A1
SCHEMBL12208682 0.73 IKBKE (0.41) TBK1IKBKESUV39H2ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 US disclosed
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2021-06-10 US disclosed
WO-2020257487-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2020-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT LGMN 272/4885TBK1 3261/4885IKBKE 1487/4885
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT LGMN 272/4885TBK1 3261/4885IKBKE 1487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.